CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar

Puma Biotechnology $PBYI CEO Alan Auerbach just beat some heavy odds weighing against neratinib.

After appealing a negative opinion adopted by the Committee for Medicinal Products for Human Use, the EMA group has reversed course and is now recommending an approval.